Phenylalanine hydroxylase variants interact with the co-chaperone DNAJC12.


Journal

Human mutation
ISSN: 1098-1004
Titre abrégé: Hum Mutat
Pays: United States
ID NLM: 9215429

Informations de publication

Date de publication:
04 2019
Historique:
received: 07 11 2018
revised: 12 01 2019
accepted: 19 01 2019
pubmed: 23 1 2019
medline: 12 3 2020
entrez: 23 1 2019
Statut: ppublish

Résumé

DNAJC12, a type III member of the HSP40/DNAJ family, has been identified as the specific co-chaperone of phenylalanine hydroxylase (PAH) and the other aromatic amino acid hydroxylases. DNAJ proteins work together with molecular chaperones of the HSP70 family to assist in proper folding and maintenance of intracellular stability of their clients. Autosomal recessive mutations in DNAJC12 were found to reduce PAH levels, leading to hyperphenylalaninemia (HPA) in patients without mutations in PAH. In this work, we investigated the interaction of normal wild-type DNAJC12 with mutant PAH in cells expressing several PAH variants associated with HPA in humans, as well as in the Enu

Identifiants

pubmed: 30667134
doi: 10.1002/humu.23712
doi:

Substances chimiques

Biomarkers 0
DNAJC12 protein, human 0
Molecular Chaperones 0
Repressor Proteins 0
Phenylalanine Hydroxylase EC 1.14.16.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

483-494

Subventions

Organisme : Research Council of Norway
ID : FRIMEDBIO 261826/F20
Pays : International
Organisme : Research Council of Norway
ID : FORNY 248889/O30
Pays : International
Organisme : K.G. Jebsen Centre for Neuropsychiatric Disorders
Pays : International
Organisme : the Western Norway Regional Health Authorities
ID : 912246
Pays : International
Organisme : European Commission
ID : FP7-HEALTH-2012-INNOVATION-1 EU
Pays : International
Organisme : European Commission
ID : 305444
Pays : International

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Kunwar Jung-Kc (K)

Department of Biomedicine, University of Bergen, Bergen, Norway.

Nastassja Himmelreich (N)

Dietmar-Hopp-Metabolic Center, University Children's Hospital, Heidelberg, Germany.

Karina S Prestegård (KS)

Department of Biomedicine, University of Bergen, Bergen, Norway.

Tie-Jun Sten Shi (TS)

Department of Biomedicine, University of Bergen, Bergen, Norway.

Tanja Scherer (T)

Division of Metabolism, University Children's Hospital Zürich, Zürich, Switzerland.

Ming Ying (M)

Department of Biomedicine, University of Bergen, Bergen, Norway.

Ana Jorge-Finnigan (A)

Department of Biomedicine, University of Bergen, Bergen, Norway.

Beat Thöny (B)

Division of Metabolism, University Children's Hospital Zürich, Zürich, Switzerland.

Nenad Blau (N)

Dietmar-Hopp-Metabolic Center, University Children's Hospital, Heidelberg, Germany.
Division of Metabolism, University Children's Hospital Zürich, Zürich, Switzerland.

Aurora Martinez (A)

Department of Biomedicine, University of Bergen, Bergen, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH